UK Markets open in 2 hrs 52 mins

Celyad Oncology SA (0QFK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.0960+0.0600 (+5.79%)
At close: 03:12PM GMT
Full screen
Previous close1.0360
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Volume150
Avg. volumeN/A
Market cap13.286M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
EPS (TTM)-1.2340
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, November 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.

  • Business Wire

    Celyad Oncology Provides Strategic Update

    MONT-SAINT-GUIBERT, Belgium, October 12, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its strategic business model, clinical trial programs, and the related operational and organizational steps and cost-saving measures that it will undertake.

  • Business Wire

    Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

    GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium, September 20, 2022--Regulatory News: Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufa